Preparation method of joint-inspection test paper for cardiac troponin I and heart-type fatty acid binding protein

Abstract

The invention discloses a preparation method of joint-inspection test paper for cardiac troponin I (cTn I) and heart-type fatty acid binding protein (H-FABP). The preparation method comprises the following steps: using a membrane-spotting metal spraying device and a mixed liquid labeled by a cTn I labeled antibody and an H-FABP labeled antibody to spray metal to a pad, so as to obtain a gold pad; using a cTn I detection line coating buffer, an H-FABP detection line coating buffer and a control line coating buffer to respectively scribe on a polyvinyl chloride base plate adhered with nitrocellulose membrane, so as to obtain the polyvinyl chloride base plate spotted with the membrane; assembling a sample pad, the gold pad, the membrane spotted polyvinyl chloride base plate and absorbent paper together, and then cutting the assembled paper to obtain the detecting test paper. With adoption of the method, the detecting test paper obtained by the invention is based on the lateral flow immune chromatography technology, and can be used by manual operation and visible reading to judge whether the blood sample contains cardiac troponin I and heart-type fatty acid binding protein, so that the diagnosis is rapid and the result is accurate, and the body of the subject can be free of damage.

Description

technical field [0001] The invention relates to the technical field of biological applications, in particular to a preparation method of a joint detection test paper for cardiac troponin I and heart-type fatty acid binding protein. Background technique [0002] Acute myocardial infarction (AMI) is a common emergency for middle-aged and elderly people. The first aid time for AMI is the key to reducing mortality. The main cause of AMI death is that it cannot be diagnosed early and delays the timing of treatment. Therefore, it is an urgent need to develop high-sensitivity and high-specificity early diagnostic reagents to improve the diagnosis rate and treatment effect of AMI and reduce the mortality rate. Traditionally, the diagnosis of AMI relies on signs of chest pain, electrocardiographic features, and serum markers. However, chest pain is not typical and the ECG is not specific. Therefore, the early detection of myocardial markers has important clinical application value....

AI Technical Summary

Problems solved by technology

[0004] Studies have shown that in the very early stage of the onset of acute myocardial infarction, H-FABP in the cytoplasm will be rapidly released into the plasma, which can directly indicate the onset of heart patients, so it can be used as an effective marker for early diagnosis of myocardial infarction; and because Its accuracy, sensitivity and specificity, there is no better AMI marker to replace it